article · Molecules
Targeting cyclin-dependent kinases represents an established approach in oncology drug discovery. Researchers synthesised two series of oxindole-indole conjugates alongside carbocycle-indole conjugates to evaluate their potential as antitumor agents targeting CDK4. In laboratory evaluations against human breast cancer MCF-7 and MDA-MB-231 cell lines, most oxindole-indole conjugates suppressed cancer cell growth, whereas replacing the oxindole ring with indane or tetralin groups significantly reduced antiproliferative activity. Among the compounds, hybrids 6e and 6f disturbed the cell cycle and stimulated apoptosis in MCF-7 cells. Enzymatic testing revealed that compounds 6a and 6e exhibited notable CDK4 inhibition. Complementary molecular docking studies demonstrated that the oxindole moiety forms hydrogen bonds with critical amino acids, while the indole group occupies an adjacent hydrophobic pocket. These findings position the compounds as prospective lead structures for targeted breast cancer drug development.
Cyclin-dependent kinases are frequently overexpressed in human tumours, making their inhibition a priority for cancer therapy development. Identifying new chemical structures that selectively block CDK4 and halt breast cancer cell growth provides valuable starting points for designing more effective medicines. The detailed structural data also helps medicinal chemists refine future drug candidates to improve binding and potency.
This work represents early-stage drug discovery suited for pharmaceutical developers and biotechnology research teams pursuing CDK4-targeted breast cancer therapies. The identified lead compounds, particularly 6a and 6e, offer structural templates for patenting, chemical optimisation, and medicinal chemistry programmes. Because testing is limited to in vitro cellular assays and computational docking, the technology remains at an early laboratory stage, requiring substantial pharmacokinetic evaluation, animal studies, and clinical trials before commercial deployment.
AI-generated from the published abstract. Always read the original work before citing.
On account of their overexpression in a wide range of human malignancies, cyclin-dependent kinases (CDKs) are among the most validated cancer targets, and their inhibition has been featured as a valuable strategy for anticancer drug discovery. In this study, a hybrid pharmacophore approach was adopted to develop two series of oxindole-indole conjugates (<b>6a-i</b> and <b>9a-f</b>) and carbocycle-indole conjugates (<b>11a</b>,<b>b)</b> as efficient antitumor agents with potential inhibitory action toward CDK4. All oxindole-indole conjugates, except <b>6i</b>, <b>9b</b>, and <b>9c</b> efficiently affected the growth of the human breast cancer MCF-7 (IC<sub>50</sub>: 0.39 ± 0.05-21.40 ± 1.58 μM) and/or MDA-MB-231 (IC<sub>50</sub>: 1.03 ± 0.04-22.54 ± 1.67 μM) cell lines, whereas bioisosteric replacement of the oxindole nucleus with indane or tetralin rings (compounds <b>11a</b>,<b>b</b>) diminished the anti-proliferative activity. In addition, hybrids <b>6e</b> and <b>6f</b> displayed effective cell cycle disturbance and proapoptotic capabilities in MCF-7 cells. Furthermore, the efficient anti-proliferative agents towards MCF-7 and/or MDA-MB-231 cell lines (<b>6a-h</b>, <b>9a</b>, and <b>9e</b>) were investigated for their potential inhibitory action toward CDK4. Hybrids <b>6a</b> and <b>6e</b> displayed good CDK4 inhibitory activity with IC<sub>50</sub>s equal 1.82 and 1.26 µM, respectively. The molecular docking study revealed that oxindole moiety is implicated in two H-bonding interactions via both (NH) and (C=O) groups with the key amino acids Glu94 and Val96, respectively, whereas the indole framework is stably accommodated in a hydrophobic sub-pocket establishing hydrophobic interactions with the amino acid residues of Ile12, Val20, and Gln98 lining this sub-pocket. Collectively, these results highlighted hybrids <b>6a</b> and <b>6e</b> as good leads for further optimization as promising antitumor drugs toward breast malignancy and CDK inhibitors.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/molecules25092031
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
